Tetrous announced the first anterior cruciate ligament (ACL) reconstruction cases completed in the U.S. and Australia using the EnFix ACL, a new 100% demineralized bone fiber (DBF) implant, as Tetrous expands into additional clinical applications in the knee.
EnFix ACL technology features FormLok shape retention that:
Directly targets the historical weaknesses of conventional ACL reconstruction.
Promotes biological regeneration at the critical graft-bone interface, addressing the primary causes of failure.
Integrates into the existing ACL reconstruction procedure without altering surgical technique or adding significant time to the procedure.
The EnFix ACL product expands on the established applications of the EnFix family of products, and works in conjunction with EnFix TAC, which is currently utilized for Lateral Extra-articular Tenodesis and Anterior Lateral Ligament Reconstruction.
“The impetus behind EnFix ACL’s development was a direct response to Enthesis Failure Syndrome, a pervasive issue characterized by poor healing at bone/tendon or bone/graft interfaces that contributes to high failure rates in numerous soft-tissue repairs. This new product is a strategic expansion of our established EnFix technology, leveraging its proven success in shoulder applications and bringing enhanced regenerative capabilities to a wider spectrum of orthopedic challenges,” said Andrew Carter, PhD, Co-founder, Director, and CTO of Tetrous.
Tetrous announced the first anterior cruciate ligament (ACL) reconstruction cases completed in the U.S. and Australia using the EnFix ACL, a new 100% demineralized bone fiber (DBF) implant, as Tetrous expands into additional clinical applications in the knee.
EnFix ACL technology features FormLok shape retention that:
Directly targets...
Tetrous announced the first anterior cruciate ligament (ACL) reconstruction cases completed in the U.S. and Australia using the EnFix ACL, a new 100% demineralized bone fiber (DBF) implant, as Tetrous expands into additional clinical applications in the knee.
EnFix ACL technology features FormLok shape retention that:
Directly targets the historical weaknesses of conventional ACL reconstruction.
Promotes biological regeneration at the critical graft-bone interface, addressing the primary causes of failure.
Integrates into the existing ACL reconstruction procedure without altering surgical technique or adding significant time to the procedure.
The EnFix ACL product expands on the established applications of the EnFix family of products, and works in conjunction with EnFix TAC, which is currently utilized for Lateral Extra-articular Tenodesis and Anterior Lateral Ligament Reconstruction.
“The impetus behind EnFix ACL’s development was a direct response to Enthesis Failure Syndrome, a pervasive issue characterized by poor healing at bone/tendon or bone/graft interfaces that contributes to high failure rates in numerous soft-tissue repairs. This new product is a strategic expansion of our established EnFix technology, leveraging its proven success in shoulder applications and bringing enhanced regenerative capabilities to a wider spectrum of orthopedic challenges,” said Andrew Carter, PhD, Co-founder, Director, and CTO of Tetrous.
Copy to clipboard 
